Insights & Opportunities. TSX Venture (OGI) OTCQB Venture Marketplace (OGRMF)

Transcription

1 Insights & Opportunities TSX Venture (OGI) OTCQB Venture Marketplace (OGRMF)

2 Disclaimer & Cautionary Statements This document is current as of September 11, The information contained in this presentation is provided by Organigram ( OGI ) for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of OGI or other financial products. The information contained herein is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of OGI nor its directors, officers, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation. Except for statements of historical fact, this presentation contains certain forward-looking information within the meaning of applicable securities laws. Forward-looking information is frequently characterized by words such as plan, expect, project, intend, believe, anticipate, estimate and other similar words, or statements that certain events or conditions may or will occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements, including, among others, OGI s crop yields, product liability, government regulation, OGI s expansion plans, as well as those risk factors identified in OGI s Q MD&A and other disclosure documents available at under OGI s name. OGI undertakes no obligation to update forward-looking information if circumstances or management s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. This presentation does not constitute an offer of shares for sale in the United States or to any person that is, or is acting for the account or benefit of, any U.S. person [as defined in Regulation S under the United States Securities Act of 1933, as amended (the Securities Act ) ( U.S. Person )], or in any other jurisdiction in which such an offer would be illegal. OGI s shares have not been and will not be registered under the Securities Act. We seek safe harbour. This document may not be reproduced, further distributed or published in whole or in part by any other person. This document may only be disseminated or transmitted into any jurisdiction in compliance with, and subject to, applicable securities laws. Readers are required to ensure their compliance with applicable securities laws. 2

3 " Meet the Executive Team

4 Investor Highlights Consumer base to grow exponentially with adult recreational market Strong Roots. in October 2018 Canada global leader in cannabis Strategic location to operate our business New Brunswick leading the cannabis charge in Canada In our plants, our people & our company. Increased production with fully-funded expansion Ready for the adult recreational market launch Brand positioning & strategic partnerships Differentiated products & brands focused on quality for the medical and adult recreational markets Team with extensive experience Cannabis, large CPG brands, beverage alcohol, pharma, finance, horticulture #

5 Organigram: Financial Snapshot Stock Data (TSXV: OGI) Stock Price $7.79 Financial Highlights Revenue (Q3-2018) $3.7M 52 Week Low/High $ $8.07 EPS $0.02 Avg. Daily Vol. (3 mo.) 1,000,000 Cash & Cash Equivalents $155.8M Basic Shares Out. Fully Diluted Shares (Excl. $5.42 debentures) Fully Diluted Shares (w/ $5.42 debentures) Valuation Measures 125M 140M 161M Debt $98M Total Assets $272M Total Liabilities $107M End of Q May 31 Share Price Performance LTM Market Cap $975M Enterprise Value $918M EV/Revenue 75x Price/Tangible Book 5.9x Note: Stock Data figures as of September 11 th, Financial highlights as of OGI s Q3-2018: May Valuation measures calculated using July 27, 2018 share price and May 31 st financial statement data. $

6 Recent Awards In November 2017, Organigram was recognized for product quality and exceptional service at the Canadian Cannabis Awards. The annual, voter-driven event recognizes best-in-class among licensed producers from coast-to-coast. Current Lift Rating 4.3/5 Stars Wabanaki Blueberry Cheesecake Compassionate Pricing %

7 Cannabis Consumption: Forecasted Exponential Growth 2017 Medical Market 2018 Adult Recreational Market Launch: October 17, Medical Revenue: $435M Patients: 269,502 Total Revenue: $8.6B! Medical & Adult recreational markets! This is 40% of the Canadian alcohol market Medical Revenue: $1.2B Patients: 450,000! As of December 31, 2017 Source: Russell Stanley, Echelon Wealth Partners &

8 8 Total Monthly Active Patients May 2017 to May 2018

9 Canadian Legislative Landscape The Canadian Federal Government recently announced that the adult recreational program marijuana will launch on October 17, Bill C-45 became law on June 21, 2018 Organigram part of select group of LPs that will have significant product volume available for the adult recreational marketplace launch Distribution will be via provincially operated stores in Ontario, Quebec, New Brunswick, Nova Scotia and PEI and via private retail stores in BC, Alberta, Saskatchewan, Manitoba and Newfoundland All online sales will be run by the province except for Saskatchewan The Opportunity for Organigram Premium high quality product Existing established customer base Increase production capacity in advance of adult recreational market launch Leadership among the competition setting standards for product quality Corporate social responsibility educating consumers on responsible usage Create and develop branded and differentiated products 9

10 We Call it Home. And it Makes Business Sense. New Brunswick One of the lowest cost locations in Canada Operating cost Real estate Utilities Wages Lowest general corporate income tax in Atlantic Canada Low and predictable base power rate of 5.2/kWh Significantly cheaper (up to 50% cheaper) than Ontario Skilled & motivated workforce Bilingual branding and services 10

11 11 Distribution Deals with Provincial Crown Corporations and other Retailers

12 )! International Target Markets

13 International Target Markets (cont.) Germany - Partnership with German Alpha-Cannabis which provides Organigram: 1) An immediate vehicle for larger scale export into the EU market. 2) The possibility to purchase synthetic CBD. 3) Strong partner for submitting an application to the soon to be released RFP for in-country cultivation (equivalent to ACMPR) from the German Health Regulatory Body (BfArM) Australia - Commence international export to Australian medical cannabis partner Cannatrek Medical through their partnership with leading global cannabis and hemp brokerage firm Cannada Management. Dealer s License - Received Dealer s License in May 2018 which allows the Company to conduct activities not permitted under ACMPR. The company can now develop, test and export an extensive range of products including its current offering of cannabis oils as well as an extensive range of derivative based products. 13

14 Strategic Investment in Hyasynth Hyasynth has developed a disruptive technology to naturally produce cannabinoids without the need to grow the cannabis plant. This is done by specifically designed strains of yeast. To produce each unique cannabinoid, the process begins by inserting genes into the yeast`s natural metabolism which cause the production of cannabinoids within the yeast. Via this process, Hyasynth has developed patented enzymes that work to convert from natural precursors to CBG, CBD and THC. Each new yeast strain can be scaled to millions of litres of fermentation. This process has the potential to create a global supply of pure cannabinoids at a fraction of a cost of a traditional cannabis cultivator 14

15 Three Level Growing Technology! Maximize footprint! 100% larger rooms in new expansion )$

16 Exponential Production Growth Fully funded (ongoing) facility expansion through Phase 4 up to 473,228 sq. ft. Expansion Specifications Target Construction Area Phase Status Date (sq. ft.) Phase 1 Complete N/A 31,600 Production capacity Present: 36,000 kg/yr April 2019: 62,000 kg/yr August 2019: 89,000 kg/yr October 2019: 113,000 kg/yr Expected pro-forma production capacity Phase 2 Complete N/A 102,125 Phase 3 Complete N/A 40,000 Phase 4a Under Construction April ,000 Phase 4b In Planning August ,000 Phase 4c In Planning October ,000 Phase 5 TBD N/A 58,503 Approx. Project Total Sq. Ft / 473,228 16

17 17 Industry Leading Yields Driving Down Costs

18 Key Performance Indicators Medical Patients >15,000 Medical Patients with an Active Prescription > $7.00 Avg. selling price per gram of dried cannabis to medical patients 15% Q/Q Sales Growth Gross sales increased from Q to Q $155 Million Cash and Cash Equivalents at Q

19 Adult Adult Recreational Recreational Portfolio Portfolio

20 Product Portfolio for the Future The Green Solution Exclusive Canadian intellectual property, product development and distribution agreement Proven market leader based in Denver, Colorado $100M + in cumulative product sales 16 retail locations 225+ unique cannabis products in portfolio Recognized and award-winning product lines Consulting to Organigram for development of: Commercial scale extraction and product processing Derivative product development ü ü ü Vaporizer cartridges and pens Proven leading edibles and beverage product mix Child-resistant packaging for all edibles and beverages 20

21 Key Take Aways! Organigram is well positioned to become a leading producer to both the medical and adult recreational markets! Medical continues to proliferate and gain acceptance! Adult recreational entering its infancy, a new market for distribution! Increasing Production and Processing Capabilities! Current production capacity of 36,000 kg per year! Fully funded to complete expansion! Will open up the recreational market! Supply MOUs in NB, MB, PEI, AB! Organigram is an efficient producer of premium quality product! All-in costs of production less than $1/gram! Average selling price over $7.00/gram! Winner of two out of six product category awards at 2017 Canadian Cannabis Awards! Positioned well for Regulatory Changes! Adult use program launch in October 2018!) Organigram was recognized as a TSX Venture 50TM company in TSX Venture 50 is a trademark of TSX Inc. and is used under license.

22 Thank You! Contact Information: Organigram Holdings Inc. 35A English Dr. Moncton, NB, E1E 3X3 Direct Line: Toll Free: Ext

23 Appendix A: Management Greg Engel Chief Executive Officer and Director Mr. Engel is a senior executive with 30 years of National and International experience in the pharmaceutical, biotechnology, cannabis and consumer packaged goods industries. Mr. Engel has led the creation, development and growth of several companies over the span of his career. An articulate and trusted voice in the burgeoning Canadian cannabis space, Mr. Engel most recently worked with a competitive licensed producer to become the first Canadian exporter of medical cannabis, as well as the establishment of several trailblazing industry standards. As leader at Organigram Inc, Mr. Engel is focused on reputational excellence through product quality and safety, expansion of the company s Moncton, N.B. facility, and production efficiencies to position the company as a leader in the Medical and Adult Recreational Cannabis industries. Mr. Engel graduated from the University of Guelph with an Honours Bachelor of Science in Microbiology. Jeff Purcell Vice President of Operations Mr. Purcell assumed the position of Vice President of Operations of Organigram Inc. on June 12, He is filling a key role on the company s Senior Leadership Team, as a seasoned professional in the areas of large scale production and facility expansion. Mr. Purcell has the responsibility and oversight for the entire production facility including production, engineering and maintenance, construction, quality assurance, safety, security and the company s vision for oils and extract products. Mr. Purcell brings over 25 years of experience to the role, most recently as Vice President of Operations at Ganong Bros. Limited with responsibilities including implementation of quality systems, safety, and continuous improvement initiatives. While in the role, he was also responsible for a significant facility expansion, essentially creating an entirely new production environment. Prior to Ganong, Mr. Purcell spent over 15 years in progressively senior roles leading operations at McCain Foods. Mr. Purcell holds a Bachelor of Commerce degree, from St. Mary s University. Paolo De Luca Chief Financial Officer Mr. De Luca joined Organigram on December 19, 2017 bringing over 20 years of diversified financial business experience. Mr. De Luca has held senior financial, investor relations, and accounting leadership roles at companies including West Face Capital, one of Canada's leading alternative asset management firms; Meridian LNG; Potash Ridge; C.A. Bancorp; and TD Securities. Raymond Gracewood Chief Commercial Officer As the previous Senior Director of Sales and Marketing for Moosehead Breweries Ltd., Mr. Gracewood is a leading brand and marketing professional in Atlantic Canada. With more than 15 years of experience in the marketing space, he is a strong speaker on brand, packaging and positioning, both locally and throughout North America. He has extensive experience in building and developing brands, positioning and segmentation. Mr. Gracewood holds a Bachelor of Business Administration degree from the University of New Brunswick. Tim Emberg Vice President of Sales and Commercial Operations Mr. Emberg is a senior sales and marketing executive with over 20 years experience in the pharmaceutical, OTC and consumer packaged goods industry. As the previous Head of Marketing & Executive Director of Sales for Roche Diabetes Care Canada, Mr. Emberg built and led several sales and marketing teams to success over the years. Mr. Emberg has also held many progressively growing commercial roles in other top-tier organizations such as Jamieson Laboratories and Frito-Lay Canada. Mr. Emberg holds a Bachelor s degree from the University of Ottawa. Guillermo Delmonte President of International Operations A proven leader in the international cannabis and CBD marketplace, Mr. Delmonte joins the Organigram team following two and a half years as Chief Executive Officer at ICC Labs Inc., a leading international hemp and cannabis producer. In this role, he successfully oversaw the ICC's initial public offering (IPO) as the first South American cannabis company to go public with a first day valuation of more than $120 million CAD. Michael Tripp Chief Legal Officer Mr. Tripp worked for private practices at respected business law firms in Moncton and Toronto where he acted on over $3 billion in transactions. 23

24 Appendix B: Board of Directors Peter Amirault Chairman Mr. Amirault is currently the President of BML Group Limited. Prior to joining BML Group, Peter held varying executive roles including: President of Swiss Chalet North America for the Cara Group of Companies, CEO of Creemore Springs Brewery Ltd, Senior Vice President of Molson Coors Canada, Managing Director of Sleeman Brewing Ltd, along with senior roles at Nestle Canada and The Premium Beer Company of Toronto. Peter holds a BBA from Acadia University and an MBA from The Schulich School of Business. Peter brings a wealth of knowledge with his previous board experience and roles at senior management levels. Derrick West Audit Committee Chair Mr. West currently serves as the Chief Financial Officer and Corporate Secretary of Partners Real Estate Investment Trust, a TSX listed issuer, and has previously served as the CFO of a TSXV listed international mining service enterprise and as the Vice- President of Accounting and Administration for a TSX listed REIT. Mr. West commenced his career with Grant Thornton LLP where he obtained his Chartered Accountancy designation and is an active Chartered Professional Accountant. Michel Bourque Director Mr. Bourque brings more than 25 years of sales and marketing leadership experience in the pharmaceutical industry, having worked in the branded Rx, generic Rx and branded/private label OTC sectors. Over this time, he has successfully led teams in the specialty medicine, hospital, and retail key account areas driving profitable growth through strategic planning and the implementation of innovative value-added programs. Mr. Bourque holds a Bachelor of Business Administration degree from l Université de Moncton. Dr. Kenneth Mitton Director Dr. Mitton is a highly respected physician, practicing in Moncton, New Brunswick. Dr. Mitton has practiced medicine for over 30 years as a family doctor. He also advises a number of large corporations in New Brunswick, with respect to occupational health matters. Dr. Mitton has previously served as the Chief of Staff of the South-East Regional Health Authority (now the Horizon Health Network) and is currently the medical director of The Moncton Hospital. Dr. Mitton holds a Bachelor of Science and a Doctor of Medicine Degree from Dalhousie University. 24

25